ArticleKidney international reports2025
Shiga Toxin-Producing
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hemolytic Uremic Syndrome Outbreak in Adults and Shiga Toxin-Producing Escherichia coli Negative for Locus of Enterocyte Effacement, France, 2025.Emerging infectious diseases · 2026Article
- Thrombotic microangiopathy after kidney transplantation: diagnosis and management strategies.Clinical kidney journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Shiga toxin (Stx)-producing Methods: We conducted a retrospective study involving adult KTRs diagnosed with STEC-HUS between January 2012 and April 2022 across 15 French nephrology centers. We aimed to characterize the clinical, biological, and microbiological features of STEC-HUS in this population, its management, and outcomes. Results: A total of 35 adult KTRs were included. The annual incidence was estimated at 14.4 cases per 100,000 KTRs. Six and 29 patients presented with localized intrarenal or systemic TMA, respectively. The median time from transplantation to STEC-HUS diagnosis was 3 (1.2-6.2) years and the mean age at diagnosis was 57 ± 13 years. Neurological and cardiac complications occurred exclusively in patients with systemic TMA. AKI and significant proteinuria were observed in 89% and 94% of patients, respectively. All patients requiring dialysis exhibited systemic TMA (38%). Treatment included azithromycin, eculizumab, and conversion from calcineurin inhibitors (CNIs) to belatacept. Graft loss and mortality rates were 26% and 9%, respectively. Conclusion: This study highlights that STEC-HUS represents a serious complication in KTRs, significantly impairing renal and overall survival. It should be systematically considered in cases of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.